Renal Tubular Acidosis an Adverse Effect of PD-1 Inhibitor Immunotherapy
Immune checkpoint blockade therapy is gaining popularity among oncologists for treatment of solid and hematologic malignancies. The widespread use of these agents resulted in increasing incidence of renal immune-related adverse events. Reported renal toxicity described so far includes acute intersti...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Case Reports in Oncological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2018/8408015 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832546531641655296 |
|---|---|
| author | Sandy El Bitar Chanudi Weerasinghe Elie El-Charabaty Marcel Odaimi |
| author_facet | Sandy El Bitar Chanudi Weerasinghe Elie El-Charabaty Marcel Odaimi |
| author_sort | Sandy El Bitar |
| collection | DOAJ |
| description | Immune checkpoint blockade therapy is gaining popularity among oncologists for treatment of solid and hematologic malignancies. The widespread use of these agents resulted in increasing incidence of renal immune-related adverse events. Reported renal toxicity described so far includes acute interstitial nephritis, minimal change disease, and immune complex glomerulonephritis. We report the case of a 79-year-old female with metastatic non-small cell lung cancer on anti-PD-1 therapy nivolumab. After the 4th administration of nivolumab, the treatment course was complicated with normal anion gap metabolic acidosis. Urine and blood studies were in favor of distal renal tubular acidosis (RTA). Following a negative workup for an underlying etiology, immunotherapy-induced RTA was suspected. Withholding of the offending agent and initiation of steroid therapy resulted in adequate response. The present report provides the first presentation of RTA as a renal immune-related adverse event secondary to nivolumab. Nephrologists and oncologists should be familiar with potentially life-threatening renal side effects induced by immune checkpoint inhibitors. |
| format | Article |
| id | doaj-art-68e3c66246b14e95a204b8f40cc3f4ff |
| institution | Kabale University |
| issn | 2090-6706 2090-6714 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Oncological Medicine |
| spelling | doaj-art-68e3c66246b14e95a204b8f40cc3f4ff2025-02-03T06:48:16ZengWileyCase Reports in Oncological Medicine2090-67062090-67142018-01-01201810.1155/2018/84080158408015Renal Tubular Acidosis an Adverse Effect of PD-1 Inhibitor ImmunotherapySandy El Bitar0Chanudi Weerasinghe1Elie El-Charabaty2Marcel Odaimi3Department of Internal Medicine, Northwell Health Staten Island University Hospital, Staten Island, NY, USADepartment of Hematology and Oncology, Northwell Health Staten Island University Hospital, Staten Island, NY, USADepartment of Nephrology, Northwell Health Staten Island University Hospital, Staten Island, NY, USADepartment of Hematology and Oncology, Northwell Health Staten Island University Hospital, Staten Island, NY, USAImmune checkpoint blockade therapy is gaining popularity among oncologists for treatment of solid and hematologic malignancies. The widespread use of these agents resulted in increasing incidence of renal immune-related adverse events. Reported renal toxicity described so far includes acute interstitial nephritis, minimal change disease, and immune complex glomerulonephritis. We report the case of a 79-year-old female with metastatic non-small cell lung cancer on anti-PD-1 therapy nivolumab. After the 4th administration of nivolumab, the treatment course was complicated with normal anion gap metabolic acidosis. Urine and blood studies were in favor of distal renal tubular acidosis (RTA). Following a negative workup for an underlying etiology, immunotherapy-induced RTA was suspected. Withholding of the offending agent and initiation of steroid therapy resulted in adequate response. The present report provides the first presentation of RTA as a renal immune-related adverse event secondary to nivolumab. Nephrologists and oncologists should be familiar with potentially life-threatening renal side effects induced by immune checkpoint inhibitors.http://dx.doi.org/10.1155/2018/8408015 |
| spellingShingle | Sandy El Bitar Chanudi Weerasinghe Elie El-Charabaty Marcel Odaimi Renal Tubular Acidosis an Adverse Effect of PD-1 Inhibitor Immunotherapy Case Reports in Oncological Medicine |
| title | Renal Tubular Acidosis an Adverse Effect of PD-1 Inhibitor Immunotherapy |
| title_full | Renal Tubular Acidosis an Adverse Effect of PD-1 Inhibitor Immunotherapy |
| title_fullStr | Renal Tubular Acidosis an Adverse Effect of PD-1 Inhibitor Immunotherapy |
| title_full_unstemmed | Renal Tubular Acidosis an Adverse Effect of PD-1 Inhibitor Immunotherapy |
| title_short | Renal Tubular Acidosis an Adverse Effect of PD-1 Inhibitor Immunotherapy |
| title_sort | renal tubular acidosis an adverse effect of pd 1 inhibitor immunotherapy |
| url | http://dx.doi.org/10.1155/2018/8408015 |
| work_keys_str_mv | AT sandyelbitar renaltubularacidosisanadverseeffectofpd1inhibitorimmunotherapy AT chanudiweerasinghe renaltubularacidosisanadverseeffectofpd1inhibitorimmunotherapy AT elieelcharabaty renaltubularacidosisanadverseeffectofpd1inhibitorimmunotherapy AT marcelodaimi renaltubularacidosisanadverseeffectofpd1inhibitorimmunotherapy |